Brief: Immuneering Submits IND Application For Phase 1/2A Trial Of IMM-1-104

Immuneering

02/09/2022 14:40

Sept 2 (Reuters) - Immuneering Corp  IMRX.O :
    * IMMUNEERING ANNOUNCES SUBMISSION OF IND APPLICATION TO THE
FDA
FOR PHASE 1/2A TRIAL OF IMM-1-104 TO TREAT ADVANCED SOLID TUMORS
WITH RAS MUTATIONS
    * IMMUNEERING CORP - EXPECT TO ENROLL OUR FIRST PATIENT IN
CLINICAL DEVELOPMENT FOR IMM-1-104 IN Q4 OF THIS YEAR
    * IMMUNEERING CORP - CONTINUES TO PREPARE FOR PLANNED PHASE
1/2A
TRIAL EVALUATING IMM-1-104
    * IMMUNEERING CORP - PLANNING TO SPONSOR RECRUITMENT OF
PATIENTS
AT FIVE INTERNATIONALLY RECOGNIZED CLINICAL SITES IN UNITED
STATES

Source text for Eikon:  ID:nGNXbXCDKX 
Further company coverage:  IMRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))